Clinical trial
A Rollover Study for Patients Who Received Tremelimumab in Other Protocols, to…
NCT00378482 · AstraZeneca, Industry · Completed
Key facts
| NCT number | NCT00378482 |
|---|---|
| Title | A Rollover Study for Patients Who Received Tremelimumab in Other Protocols, to Allow the Patients Access to Tremelimumab Until This Agent Becomes Commercially Available or Development is Discontinued. |
| Official title | A Rollover Protocol For Patients Who Received Tremelimumab (CP-675,206 ) In Other Protocols |
| Lead sponsor | AstraZeneca, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Colorectal Neoplasms, Melanoma, Prostatic Neoplasms, Renal Cell Carcinoma, Neoplasms, Patients Who Have/Have Had Melanoma and Other Tumors |
| Intervention type | Drug |
| Interventions | CP-675, 206 (Tremelimumab) |
| Enrollment | 37 |
| Start date | Mar 5, 2007 |
| Primary completion | Oct 27, 2023 |
| Completion | Oct 27, 2023 |
| First posted | Sep 20, 2006 |
| Last update posted | Aug 22, 2024 |
| Countries | United Kingdom, United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: